US20030157168A1 - Sequestered antagonist formulations - Google Patents

Sequestered antagonist formulations Download PDF

Info

Publication number
US20030157168A1
US20030157168A1 US10/214,408 US21440802A US2003157168A1 US 20030157168 A1 US20030157168 A1 US 20030157168A1 US 21440802 A US21440802 A US 21440802A US 2003157168 A1 US2003157168 A1 US 2003157168A1
Authority
US
United States
Prior art keywords
dosage form
antagonist
naltrexone
intact
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/214,408
Inventor
Christopher Breder
Benjamin Oshlack
Curtis Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Euroceltique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US31053301P priority Critical
Application filed by Euroceltique SA filed Critical Euroceltique SA
Priority to US10/214,408 priority patent/US20030157168A1/en
Assigned to EURO-CELTIQUE S.A. reassignment EURO-CELTIQUE S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BREDER, CHRISTOPHER, WRIGHT, CURTIS, OSHLACK, BENJAMIN
Publication of US20030157168A1 publication Critical patent/US20030157168A1/en
Assigned to PURDUE PHARMA L.P. reassignment PURDUE PHARMA L.P. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EURO-CELTIQUE S.A.
Application status is Abandoned legal-status Critical

Links